Member Info for Matml74

There have been plenty of big deals over the past 18 months. AIM will not value this company efficiently until the cash is banked.

This play IMO is a buyout prior to the significant high margin auto royalties which really start to flow in 2025. Deals like this, gaining further auto market share and then the golden goose…… Gen3 aftermarket….: will determine the buyout figure but I am betting it is significantly north of where the current marketcap sits.

“ This would put GGP to the sword on their debt financing and - perhaps - shake the tree hard enough that they’d agree terms for their 30%.”

……. If that is the case then please step forward Wyloo Metals. “ We are proud to be supporting Greatland to develop WA’s next copper-gold mine into a low cost, modern mining operation with very high environmental and social standards.”

It seems to me that SD and the board have foreseen potential events of this nature and also the opportunities that may arise from them and have sought the backing of Mr A Forrest.

“ the program has been awarded with certain minimum volume guarantees, covering a number of vehicle models with start of production scheduled from early 2024 and an initial value of a$27 million, bringing the total number of oem customers to 10. the program will be delivered via company's embedded driver monitoring engine (fovio e-dme software library), pre-integrated and optimised for qualcomm's 3rd generation snapdragon® ****pit platforms.”

“business as usual”

Redirons, That is my point. The sunset clause as part of the JV contract means that the delivery of the FS will occur before April 2024 no matter what transpires between NEM/NCM in the coming months.

Starbright,

SD stated in his most recent interview that there is a sunset cluase with respect to the delivery of a feasibility study which expires April 2024.

So worst case scenario a FS has to be delivered before this date. Its highly likely that the NCM/NEM takeover will not have completed by that stage, even if terms are agreed and a positive shareholder vote occurs in the next couple of months.

Really? Are they mining it this week and selling at spot? Give me a break. It means Jack ****e until it starts coming out of the ground and is due to be sold which won’t be for another 12 months or so.

Brockwl,

I didn’t say you got the wrong number I asked where you got it!

Having now seen your reasoning I know you made it up.

There is no breakdown of which OEM’s contribute to the 173,000 odd cars that had SEE dms in the quarter….. yet you tried to imply there was an issue in the reporting of SEE wrt to bluecruise.

The 56,000 reported bluecruise numbers by Ford could very simply be included in the 173,000 reported by SEE.

Brockwl,

Where did you get the 32k blue cruise units reported by SEE from? I cant find a breakdown of OEM dms in that rns.

"Others can sell generic velcade so why would anyone buy / prescribe it at a higher patent med price if it’s only as good as generic versions of the already approved drug."

There would be no/reduced side effects. That is the whole point of the technology and what appears to be shown in the preclinical.

If you are that impressed with the SEYE CEO why would you not just go and invest in that company instead of *****ing on here.

Why anyone would invest in a company that they don’t have faith in the management is beyond my comprehension. Shows a completely disregard for the management of their own personal wealth.

If you ask a stupid question expect a stupid response in return. FFS some people need to grow up and take some personal responsibility for their investment decisions rather than cry on a bulletin board.

You have had plenty of opportunity to sell at 12p over the years.

“ What happens on a daily basis at Seeing Machines?”

Yep last set of trading accounts suggests they sit around twiddling their thumbs all morning, crank up the barbie at lunchtime and smash through a case of VB all arvo.

Gallmat,

Efficacy will be tested in Phase 1b. Trials are often stopped on ethical grounds if the proposed treatment is showing significant advantage over comparator. According to the SD slide there will be direct comparison against dox, so whilst the trial protocol might suggest a lengthy P1b there are scenario’s whereby that may not eventuate. Based on the data so far, the complete understanding of doxorubicin as a cancer treatment, the company and investors will have an understanding of the value of its first clinical candidate within the next 12 months.

Says Martin Ive has over 8m shares but he only has 6,633,556 so pay zero attention to any of that. Same goes for Morningstar data.

“RNS just out seems to confirm my point about HC!!”

Why? The quarterly payment was due this week so this rns was expected. They now have received over 3% of the company so in the next few quarters it will be revealed if they are selling or not.

"does however seem to show there’s not much above or below it. Let’s hope it goes laterally though and it’s a huge sideways slab of gold. You just never know, but the nugget effect is true."

RNS states open at depth so you don't know what is below it.

“ However, recruitment for P1b has started and thus ethics approval has been given. Start date cannot be that far away.”

Can you clarify why you think recruitment has started?

AS said in his most recent interview P1b will start after an MTD or recommended dose is established from the remaining 1a cohorts. He also stated it would take a couple of months to move from completion of 1a to starting of 1b part of the phase 1.

Agree there are catalysts which can give this a kick start in 2023 and I fully expect a number of OEM contract wins.

I do hope you are correct with Fleet as that is the upside the market is not expecting.

GL.

“ Loads of tech rebounding, Netflix, Meta, Tesla Nvidia to name a few:”

These are huge multi billion dollar companies. Comparing a tiny unprofitable microcap to these companies is absolutely ridiculous.

There will be no significant rerate of SEE share price until interest rates turn and funds flow back into riskier growth equities.

As long as the company ensures it is executing through this down market and does it’s upmost to maintain or grow market share then the SP will take care of itself eventually…… but I doubt it will be in 2023.

I suggest you check again…….. and as for ‘moving the needle’ the stock price here went down shortly after SEE won the largest ever DMS contract. If you think contract wins are going to ‘move the needle’ in the current macro you are mistaken. Until the interest rate cycle turns SEE share price will struggle.

Thu, 22nd Dec 2022 07:02

RNS Number : 5959K
Seeing Machines Limited
22 December 2022

This announcement contains inside information



Seeing Machines Limited ("Seeing Machines" or the "Company")





22 December 2022



Seeing Machines appointed to deliver additional DMS OEM program



Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, has been appointed by an existing Tier-1 customer to deliver its FOVIO Driver and Occupant Monitoring System (DMS/OMS) for an additional program with an existing large European-based global automotive group (OEM) customer.



This program, to be delivered via Seeing Machines' embedded Driver Monitoring Engine (FOVIO e-DME software library), is geared to lower integration cost and will substantially extend DMS and OMS reach across a broad range of vehicle models (including entry level vehicles), while addressing both regulatory requirements and in-cabin comfort and convenience oriented features. The program carries an initial lifetime value of US$32M (A$45M) and is scheduled to start production in 2024.



Seeing Machines continues to grow as an automotive technology leader in Driver and Occupant Monitoring Systems, having now won a total of 15 automotive programs spanning 10 individual OEMs, covering more than 160 distinct vehicle models. The cumulative initial lifetime value of all OEM programs that Seeing Machines has won to date now stands at US$321M (A$435M).



Nick DiFiore, SVP and GM Automotive commented:



"This is a great example of our existing Tier 1 and OEM relationships and cooperation leading to the increasingly extended reach of our technology across the global passenger vehicle landscape, which is not only driven by driver safety regulation but also an increasing demand for interior monitoring systems extending the comfort, convenience, and safety of all vehicle occupants."



The person responsible for this announcement is Paul McGlone, CEO.